



The DCRC group at the Brussels (Belgium) workshop, February 2012.

Further information about the DCSG:

ORGANISATION

The DCRC has been in place since 2010 and is the core business of the DCSG.

A workshop format has been adopted for sharing data and methods. Inevitably, each registry/database differs in terms (for example) of the types of data it has proved possible to capture, the ways in which these data are stored and retrieved, the period of observation, and legal constraints regarding data access and sharing. Considerable progress has however been made in overcoming these obstacles, and

the first joint analyses can now be undertaken, as described below.

The name 'Diabetes and Cancer Research Consortium' will be retained (in addition to the DCSG) as it emphasises the key research aim of this group.

This format of annual workshop and annual steering group meeting has worked effectively, and will be the format for the new DCSG.

The workshops will be announced on the Study Group website.

FINANCES

Currently, the DCSG does not hold a bank account. Senior members of the DCRC consortium are encouraged to host a two-day workshop. Funding is through local and regional means, specific to the individual host.

The host may seek funding from industry to support the workshop, but industry representation is not allowed at the workshop.

Financial support is used for travel, accommodation and meals during the annual workshop, with limits set by the host as required. If financial difficulties arise, the host may request subsidies from attending members.

There will be no rolling DCSG bank account.

DCSG MEMBERSHIP

A core business and activity of the DCSG is the Diabetes and Cancer Research Consortium (DCRC), and its workshops.

The member of the DCRC (and DCSG) is multi-disciplinary – including diabetologists, oncologists, statisticians, epidemiologists, bio-informatists, and cancer registry-based investigators.

A central principle to DCRC membership is 'consortium-based' – a willingness to share methodologies and data.

All recipients of ESFD grant awards linked to the epidemiology of diabetes and cancer are invited to be members.

DCSG EXECUTIVE COMMITTEE AND OFFICERS

The members of the Group will elect, amongst themselves during the DCRC business workshop by democratic process of all those members present, the Officers of the Executive Committee.

These will consist of a Chairman (3 years), Vice-Chairman (3 years), Secretary (4 years) and Treasurer (4 years) and normally at least 4 additional Executive Committee Members (3 years) representing the key contributing countries to the consortium.

Members of the Committee are re-electable but should not serve for more than two consecutive terms. DCSG will normally ensure that no more than two or three committee members will retire in any one year.

A sub-group of the Executive Committee, including the Chairman, will decide upon the structure of the annual workshop, final programme selection.

The Group shall normally meet on an annual basis for a scientific workshop. A business meeting of the Executive Committee will normally meeting as part of the main meeting of the EASD.

The DCSG will submit annually to the EASD a written report of activities for inclusion amongst the EASD pages of Diabetologia. It is expected that at least one member of the DCSG Executive Committee will attend the annual EASD General Assembly.

AFFILIATED ORGANISATIONS

- European Association for the Study of Obesity (EASO) <http://easo.org/>
- European Cancer Organisation (ECCO) <http://www.ecco-org.eu/>
- European Coalition for Diabetes (ECD) <http://www.ecdiabetes.eu/>
- Alliance for European Diabetes Research (EURADIA) <http://www.euradia.org/>
- PHARMO <http://www.pharmo.nl/>
- Steno Diabetes Centre <http://www.novonordiskfonden.dk/en/content/steno-diabetes-center>
- Cancer Risk and Insulin analogues (CARING) <http://www.caring-diabetes.eu/?q=content/general-introduction-0>
- Farr Institute <http://www.farrinstitute.org/>
- Primary Care Diabetes Europe <http://www.pcdeurope.org/dawn/>

OUR PUBLICATIONS

[1] Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG (2012) Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia

[2] Renehan AG (2012) Insulin analogues and cancer risk: the emergence of second-generation studies. Diabetologia 55: 7-9

[3] Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H (2012) Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia

[4] Badrick E, Renehan AG (2014) Diabetes and cancer: 5 years into the recent controversy. Eur J Cancer 50: 2119-2125

[5] Zanders MM, Renehan AG, Bowker SL, Carstensen B, van de Poll-Franse LV, Johnson JA (2014) Comment on Bordeleau et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 2014;37:1360-1366. Diabetes Care 37: e221-222

[6] Levin D, Bell S, Sund R, et al. (2015) Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58: 493-504

EXECUTIVE COMMITTEE

Officers

- **Chairman**
Andrew Renehan, UK
- **Vice Chairman**
Jeff Johnson, Canada
- **Scientific Secretary**
Bendix Carstensen, Denmark
- **Treasurer**
Soffia Ggudbjornsdottir, Sweden

Committee Members

- Sarah Wild, Scotland
- Lonneke van de Poll-Franse, The Netherlands
- Henrik Moller, England
- Edwin Gale, England (founding member)
- Ulf Smith, Sweden (founding member)

CONTACT

Study Group chair:

Professor Andrew G Renehan PhD FRCS
Professor of Cancer Studies and Surgery
The Christie NHS Foundation Trust
Faculty Institute of Cancer Sciences
University of Manchester
Manchester Academic Health Science Centre
Email: andrew.renehan@ics.manchester.ac.uk

Study Group vice-chair:

Professor Jeffrey Johnson
Alliance for Canadian Health Outcomes Research in Diabetes (ACHORD)
School of Public Health,
University of Alberta
jeffreyj@ualberta.ca

Communications officer:

Stephen Melia

Communications and Public Engagement Officer
Health eResearch Centre (HeRC)
University of Manchester
Email: stephen.melia@manchester.ac.uk